
The challenge isn't simply making more compounds. It's making the right compounds. A compound that delivers strong potency may still fail because of poor selectivity, solubility, permeability, metabolic stability or other drug-like properties.
Our medicinal chemists use the data generated throughout your program to make informed design decisions. By connecting structure activity relationship (SAR), biological activity, physicochemical properties, and ADME/DMPK data, we help you prioritize the chemistry most likely to improve your overall compound profile. This means your medicinal chemistry program is focused on learning and progression, rather than simply increasing the number of compounds made.
From hit identification and hit-to-lead through to lead optimization and candidate selection, Concept Life Sciences provides the specialist medicinal chemistry expertise and flexible capacity you need to keep your drug discovery program moving. Wherever you are in your program, we help turn your data into your next decision.
Your question: Have you identified promising activity but don't know which chemical series to pursue?
How we help: Expand and validate chemical series, investigate early SAR and prioritize compounds for further progression.
What this means for your program: A clear understanding of the chemistry worth prioritizing.
Your question: Do you need to turn an interesting hit into a credible lead series?
How we help: Design and synthesize focused compounds, establish SAR, explore chemical space and determine early drug-like properties.
What this means for your program: A credible lead series with defined SAR and improving drug-like properties.
Your question: Is potency improving but the overall compound profile isn't?
How we help: Multiple parameter optimization (MPO) - Optimize potency, selectivity, physicochemical properties and ADME/DMPK characteristics together.
What this means for your program: Compounds with an improved balance of potency, selectivity and developability to progress.
Your question: How do you identify the molecule with the best chance of progressing?
How we help: Consider the best balance of properties, chemistry, biology and ADME/DMPK data to assess the overall compound profile against your progression criteria.
What this means for your program: Greater confidence in selecting the molecule with the most promising profile to move into preclinical development.
Iterate and optimize: Every cycle generates learning that informs the next compound design.
Interesting chemistry can quickly become a bottleneck when you lack the capacity, expertise, or data needed to decide what to make, test, and progress. Medicinal chemistry expertise helps you turn promising compounds into stronger hits, leads, and candidates through an iterative Design-Make-Test-Analyze (DMTA) approach.
By connecting compound design and synthesis with biology, computer aided drug design (CADD) and ADME/DMPK, you can understand not only whether a molecule works, but why it works, where it falls short and what to make next.

Use SAR, CADD, molecular modeling, pharmacophores, scaffold hopping and existing biological and ADME data to prioritize compounds.
Develop appropriate synthetic routes and prepare the compounds required to answer the next scientific question.
Assess potency, selectivity, efficacy, target engagement and other relevant biological characteristics.
Interpret SAR alongside ADME/DMPK, physicochemical and other program data to identify the next opportunity.
Feed the learning from each cycle into the next design hypothesis.
The result: fewer uninformative compounds, more actionable data, and a clearer path towards candidate selection.
Extend your existing team without building the capability in-house.
Our medicinal chemists can support compound design, synthesis, SAR development, and optimization as an extension of your team. This is particularly valuable for biotech and virtual biotech companies that need specialist chemistry expertise or laboratory capacity without the cost and commitment of establishing a complete internal function.
Build the SAR and compound profile needed to decide which chemistry deserves further investment.
We design and synthesize focused compounds to explore chemical space, test SAR hypotheses, and address early drug-like properties. Our hit-to-lead expertise connects medicinal chemistry with biological screening and ADME/DMPK to support informed progression.
Optimize the whole compound profile, not potency in isolation. Lead optimization requires balancing multiple properties simultaneously. We can help optimize:
The objective is to identify compounds with the overall characteristic properties needed for progression, not just the most potent.
What if every compound you make could tell you what to make next?
Disconnected data can make it difficult to know what your next experiment should be. At Concept Life Sciences, medicinal chemistry can connect directly with biology, CADD, and ADME/DMPK, allowing our scientists to interpret the complete compound profile and use that information to guide the next design decision.
This integrated approach helps shorten the gap between generating data and acting on it, supporting faster and more informed decisions throughout hit expansion, hit-to-lead, and lead optimization.
You don't just need someone to synthesize your compounds. You need scientists who understand what the results mean for your program.
| Your challenge | What you need | Our solution |
|---|---|---|
| Limited in-house chemistry capacity | Specialist expertise without building a new team | Experienced medicinal chemists and laboratory infrastructure available as an extension of your team |
| Too much chemistry data, not enough direction | Clear scientific interpretation | Chemistry connected with biology, CADD and ADME/DMPK |
| Potency isn't translating into a better candidate | Multi-parameter optimization | Balance potency, selectivity, physicochemical and ADME/DMPK properties |
| Program decisions are taking too long | Connected disciplines and fewer hand-offs | Integrated multidisciplinary discovery capabilities |
| You need senior scientific input | Experienced scientists who understand the wider program | Close scientific involvement in program strategy and delivery |
| You need flexibility | Support that changes as your program evolves | Stand-alone chemistry, defined work packages or integrated drug discovery |
Specialist medicinal chemistry expertise - Our medicinal chemists bring experience across therapeutic areas, target classes, and established and emerging modalities.
Integrated drug discovery - Connect medicinal chemistry with CADD, biology, ADME/DMPK, and other discovery capabilities rather than managing disconnected workstreams.
Flexible scientific support - Work with us as an extension of your team, for a defined chemistry challenge or as part of an integrated discovery program. We remain with you throughout your project.
Data-led decision making - Use biological, chemical, and ADME/DMPK data together to understand SAR and identify the next most informative compounds.
Program-focused scientific leadership - We focus on your progression criteria and development goals, not simply the delivery of individual chemistry activities.
Your chemistry program needs more than technical capability. It needs experience applying that capability to real drug discovery decisions. Our medicinal chemists have:
Drug discovery is evolving. Our medicinal chemistry experience spans established and emerging modalities, including:
Small molecules - Design and optimization of conventional small-molecule drug candidates
PROTACs - Medicinal chemistry strategies for targeted protein degradation programs
Peptides - Design and synthesis support for peptide-based discovery programs
and other emerging modalities with flexible chemistry support tailored to the specific challenges of your program.
Different programs need different levels of support.
| Extend your team | Solve a specific challenge | Integrate your discovery program |
|---|---|---|
| Already have your discovery strategy? Add experienced medicinal chemistry capacity without investing in additional laboratory infrastructure or recruitment. |
Need specialist expertise at a critical point? Bring our scientists into a defined work package or program challenge, from compound design and SAR through to lead optimization. |
Need chemistry, biology and ADME working together? Connect medicinal chemistry with our wider discovery capabilities to create a joined-up DMTA workflow. |
| Best for: Compound synthesis, SAR programs and additional chemistry capacity. |
Best for: Specialist chemistry expertise, difficult chemistry and program bottlenecks. |
Best for: Hit-to-lead, lead optimization and integrated drug discovery. |
Whether you have a promising hit, a suboptimal lead, or a chemistry capacity gap, our medicinal chemistry experts can help you determine what to do next. Ready to discuss your program?
A: Medicinal chemistry is the design, synthesis, and optimization of chemical compounds with the aim of developing them into medicines. It combines chemistry with biological and drug development data to understand how changes in molecular structure affect potency, selectivity, physicochemical properties, ADME, and other characteristics important for candidate progression.
A: Medicinal chemistry services provide specialist support for designing, synthesizing, and optimizing compounds throughout drug discovery. Services can include compound design, synthesis, SAR development, hit-to-lead, lead optimization, and candidate selection.
A: Hit-to-lead medicinal chemistry turns promising hit compounds into more thoroughly characterized lead series. This typically involves expanding chemical series, establishing SAR, exploring chemical space, and improving early drug-like properties.
A: Lead optimization is the process of improving a lead compound's overall profile so it is suitable for progression towards a development candidate. Medicinal chemists optimize properties such as potency, selectivity, efficacy, solubility, permeability, metabolic stability, and other ADME/DMPK characteristics.
A: DMTA is an iterative drug discovery process in which compounds are designed, synthesized, tested, and analyzed, with the results informing the next round of compound design. The approach creates a continuous learning cycle for compound optimization.
A: Yes. Concept Life Sciences can connect medicinal chemistry with biological and ADME/DMPK data to help interpret the overall compound profile and determine what to make next.
A: Yes. Our medicinal chemists can work as an extension of your existing team, providing specialist expertise and laboratory capacity without requiring you to establish the capability internally.
A: Yes. The team has experience across specialist areas including PROTACs, peptides, peptide conjugates and Direct-to-Biology, alongside broader medicinal chemistry programs.
A: Concept Life Sciences combines specialist medicinal chemistry with multidisciplinary drug discovery expertise on one site, enabling efficient DMTA cycles. Rather than focusing solely on compound synthesis, our approach connects chemistry with biology, CADD, and ADME/DMPK so that data can be used to guide the next compound design and progression decision. Additionally, our dedicated senior experts remain connected with your project as project leaders or advisors throughout the collaboration duration.

